Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 68
CEO Dr. Anat Cohen-Dayag
Address Azrieli Center 26 Harokmim Street, Holon, TA 58858
Phone 972.3.765.8585
Website www.cgen.com

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Compugen Ltd. -7.49% -53.05%
Ventyx Biosciences, Inc. n/a n/a
Rani Therapeutics Holdings, Inc. n/a n/a
Aclaris Therapeutics, Inc. 2.09% 278.59%
Avidity Biosciences, Inc. -8.98% -21.66%

Statement Summary

as of 4:00 ET PM 10/20/2021
Total Assets (MRQ) 122.8 M
Total Liabilities (MRQ) 19.4 M
Shareholders’ Equity (MRQ) 103.4 M
Total Revenue (Annual) n/a
Net Income (Annual) -9.5 M

Earnings And Estimates

as of 4:00 ET PM 10/20/2021

Current Qtr EPS Estimate -0.12
Current FY EPS Estimate -0.47
Long Term EPS Growth Estimate n/a
Next Expected Earnings Date //

CGEN vs S&P 500

as of 10/20/2021
Relative To
S&P 500
CGEN
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 10/20/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.12 -0.11 -9.07%
03/2021 -0.13 -0.12 -4.55%
12/2020 -0.10 -0.10 -1.41%
09/2020 -0.09 -0.09 +5.00%
06/2020 -0.10 -0.08 -22.22%
03/2020 -0.10 -0.10 0.00%
12/2019 -0.11 -0.10 -6.25%
09/2019 -0.11 -0.10 -4.76%

Financial Strength

as of 4:00 ET PM 10/20/2021
Pre-Tax Margin 0.00
Net Margin 0.00
Operating Margin 0.00
Return On Equity -30.68
Return On Assets -26.59
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) -26.43

Ratios

as of 4:00 PM ET 10/20/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 5.31
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 1.23
Quick Ratio (MRQ) 9.60
Current Ratio (MRQ) 9.60
Total Debt/Equity (MRQ) 0.03

Short Interest

as of 4:00 PM ET 10/21/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 10/20/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.12 $-0.13
# of Estimates 7 7
High Estimate $-0.09 $-0.10
Low Estimate $-0.13 $-0.16
Year Ago EPS $-0.09 $-0.10
Year Over Year Growth Estimate 28.62% 27.07%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-0.47 $-0.58
# of Estimates 7 7
High Estimate $-0.42 $-0.37
Low Estimate $-0.52 $-0.65
Year Ago EPS $-0.37 $-0.47
Year Over Year Growth Estimate 26.64% 23.17%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.12 $-0.13 $-0.47 $-0.58
# of Estimates 7 7 7 7
High Estimate $-0.09 $-0.10 $-0.42 $-0.37
Low Estimate $-0.13 $-0.16 $-0.52 $-0.65
Year Ago EPS $-0.09 $-0.10 $-0.37 $-0.47
Year Over Year Growth Estimate 28.62% 27.07% 26.64% 23.17%

Insider Information Summary

as of 09/30/2021
% Insiders - 0.07%
% Remaining Total Shares - 99.93%
Current 1 Month
Net Insider Transaction 0.00 0.00
Shares Bought 0.00 0.00
Shares Sold 0.00 0.00

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

23andMe Lead

23andMe Stock Drops on Plan to Buy Health Platform Lemonaid

23andMe shares drop after the consumer genetics company definitively agrees to pay $400 million for health platform Lemonaid.

Pfizer vaccine Lead

Pfizer-BioNTech Covid Vaccine Shows Efficacy Above 90% for Kids

Pfizer and BioNTech's children's Covid-19 vaccine should be the topic of discussion when the FDA's vaccine advisory committee meets Tuesday.

Tesla Lead

Tesla Stock Hits Record High, With $1 Trillion Valuation In Sight, After Q3 Earnings Surge

Tesla is now within clear sight of a $1 trillion valuation after shares in the group hit a fresh all-time high following record third quarter earnings earlier this week.

Zoom Five9 Lead

Zoom Video Stock Rises After JPMorgan Upgrade

JPMorgan analyst upgraded Zoom Video and said the videoconferencing app could be a winner in enterprise or B2B communication.

trump-questions (1)

Digital World, SPAC Tied to Trump, More Than Doubles

Shares of Digital World, the SPAC through which Trump Media & Technology Group is going public, as much as more than doubled on Friday.

Beyond Meat Sausage Breakfast Yuck Lead

Beyond Meat Drops as It Lowers Q3 Revenue Expectations

Beyond Meat slashed it third quarter revenue forecast Friday, citing weakening demand, supply chain disruptions and the lingering impact of COVID-19.

Why Whirlpool Shares Have Room to Climb

Whirlpool Stock Drops as Ongoing Supply Chain Issues Impact Sales

Whirlpool shares fall after reporting mixed results for the quarter, topping bottom-line estimates while missing on revenue amid ongoing supply chain woes.

Snap Lead

Premarket Movers Friday - Snap, Digital World Trump SPAC, Intel

Stocks moving in premarket trading include Snap, Digital World (the Trump SPAC), Intel, Mattel and Zoom.

Cleveland-Cliffs to Buy AK Steel for $1.1 Billion

Cleveland-Cliffs Stock Leaps After Q3 Earnings Beat, Steel Price Outlook

Cleveland-Cliffs forecast higher average steel selling prices for next year, adding to the market reaction to stronger-than-expected third quarter earnings.

Wall Street NYSE Lead

Stock Market Live: S&P 500, Dow Hit Fresh Record Highs, Tech Hit By Snap Ad Spend Warning

Both the Dow and the S&P 500 hit a fresh record highs Friday, but tech stocks are lagging thanks to a warning on ad spending from Snap and another move north in Treasury bond yields.